Cardiogenesis ploughs on with US efforts for heart laser device
This article was originally published in Clinica
Executive Summary
Following a catalogue of setbacks in its attempt to gain US market approval for its percutaneous heart laser device for treating angina, Cardiogenesis has submitted to the FDA a trial protocol to initiate yet another study of the controversial treatment.